Larry D Anderson Jr, MD, PhD

Agha ME et al. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. ASCO 2021;Abstract 8013.

Berdeja JG et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet 2021;398(10297):314-24. Abstract

Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705-16. Abstract

Morie A Gertz, MD, MACP

Facon T et al. Overall survival results with daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Phase 3 MAIA study. EHA 2021;Abstract LB1901.

Gay F et al. Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized FORTE trial. ASH 2020;Abstract 141.

Voorhees PM et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated efficacy and safety analysis of the safety run-in population of GRIFFIN. ASH 2020;Abstract 3243.

Irene M Ghobrial, MD

Bahlis NJ et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 2021;39(32):3602-12. Abstract

Berdeja JG et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). ASCO 2021;Abstract 8008.

Gupta VA et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 2021;137(26):3604-15. Abstract

Robert Z Orlowski, MD, PhD

Gasparetto C et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. eJHaem 2020;2(1):56-65. Abstract

Mikhael J et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma Myeloma Leuk 2020:20(6):351-7. Abstract

Moreau P et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet 2021;397(10292):2361-71. Abstract

Peter Voorhees, MD

Bal S et al. Treatment outcomes of triple class refractory multiple myeloma: A benchmark for new therapies. Leukemia 2021;[Online ahead of print]. Abstract

Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract

Usmani SZ et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398(10301):665-74. Abstract